Gainers

• Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) stock moved upwards by 31.8% to $0.1 during Tuesday's regular session.
• Liminatus Pharma (NASDAQ:LIMN) stock rose 26.26% to $0.72. The company's market cap stands at $15.4 million.
• Adlai Nortye (NASDAQ:ANL) stock rose 24.59% to $11.55. The market value of their outstanding shares is at $342.0 million.
• DaVita (NYSE:DVA) stock increased by 21.04% to $134.59. The company's market cap stands at $7.8 billion. As per the news, the Q4 earnings report came out yesterday.
• Anbio Biotechnology (NASDAQ:NNNN) shares increased by 19.62% to $29.5. The market value of their outstanding shares is at $1.0 billion.
• ProMIS Neurosciences (NASDAQ:PMN) shares rose 19.32% to $16.77. The company's market cap stands at $30.2 million.

Losers

• Sangamo Therapeutics (NASDAQ:SGMO) shares fell 30.3% to $0.4 during Tuesday's regular session. The company's market cap stands at $191.0 million.
• NovaBay Pharmaceuticals (AMEX:NBY) stock decreased by 22.3% to $1.33. The market value of their outstanding shares is at $215.7 million.
• National Research (NASDAQ:NRC) stock fell 21.65% to $17.16. The company's market cap stands at $496.1 million. As per the press release, Q4 earnings came out today.
• Ernexa Therapeutics (NASDAQ:ERNA) shares declined by 20.57% to $0.98. The market value of their outstanding shares is at $9.7 million.
• CorVel (NASDAQ:CRVL) shares declined by 16.75% to $58.07. The market value of their outstanding shares is at $3.5 billion. As per the news, the Q3 earnings report came out today.
• bioAffinity Technologies (NASDAQ:BIAF) stock declined by 16.15% to $1.06. The market value of their outstanding shares is at $5.7 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.